<?xml version='1.0' encoding='utf-8'?>
<document id="29460901"><sentence text="[The clinical significance of the lamotrigine pharmacokinetic variability]."><entity charOffset="34-45" id="DDI-PubMed.29460901.s1.e0" text="lamotrigine" /></sentence><sentence text="To estimate pharmacokinetic variability of lamotrigine (LTG) and its clinical significance"><entity charOffset="43-54" id="DDI-PubMed.29460901.s2.e0" text="lamotrigine" /><entity charOffset="56-59" id="DDI-PubMed.29460901.s2.e1" text="LTG" /><pair ddi="false" e1="DDI-PubMed.29460901.s2.e0" e2="DDI-PubMed.29460901.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29460901.s2.e0" e2="DDI-PubMed.29460901.s2.e1" /></sentence><sentence text="" /><sentence text="One hundred patients, including 74 women, aged from 18 to 77 years (38" /><sentence text="23±14" /><sentence text="37 years), with focal epilepsy were examined" /><sentence text=" Monotherapy with LTG was administered to 54 patients, duotherapy to 46 patients (LTG and valproic acid combination to 27 patients, LTG and liver enzymes inducers to 19 patients)"><entity charOffset="90-103" id="DDI-PubMed.29460901.s7.e0" text="valproic acid" /><entity charOffset="18-30" id="DDI-PubMed.29460901.s7.e1" text="LTG" /><entity charOffset="82-94" id="DDI-PubMed.29460901.s7.e2" text="LTG" /><entity charOffset="132-144" id="DDI-PubMed.29460901.s7.e3" text="LTG" /><pair ddi="false" e1="DDI-PubMed.29460901.s7.e1" e2="DDI-PubMed.29460901.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29460901.s7.e1" e2="DDI-PubMed.29460901.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29460901.s7.e1" e2="DDI-PubMed.29460901.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29460901.s7.e1" e2="DDI-PubMed.29460901.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29460901.s7.e2" e2="DDI-PubMed.29460901.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29460901.s7.e2" e2="DDI-PubMed.29460901.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29460901.s7.e2" e2="DDI-PubMed.29460901.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29460901.s7.e0" e2="DDI-PubMed.29460901.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29460901.s7.e0" e2="DDI-PubMed.29460901.s7.e3" /></sentence><sentence text=" Patients underwent procedures of therapeutic drug monitoring (TDM)" /><sentence text=" Minimal (Cssmin) and maximal (Cssmax) steady-state LTG plasma concentrations, and concentration-to-weight ratio (CDR) were calculated"><entity charOffset="52-54" id="DDI-PubMed.29460901.s9.e0" text="LTG" /></sentence><sentence text="" /><sentence text="In patients who used LTG in monotherapy, LTG Cssmin was 5"><entity charOffset="21-23" id="DDI-PubMed.29460901.s11.e0" text="LTG" /><entity charOffset="41-43" id="DDI-PubMed.29460901.s11.e1" text="LTG" /><pair ddi="false" e1="DDI-PubMed.29460901.s11.e0" e2="DDI-PubMed.29460901.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29460901.s11.e0" e2="DDI-PubMed.29460901.s11.e1" /></sentence><sentence text="6±4" /><sentence text="65 mg/l, Cssmax 7" /><sentence text="59±5" /><sentence text="54 mg/l" /><sentence text=" In the group that received LTG in combination with valproate, LTG Сssmin was 7"><entity charOffset="52-61" id="DDI-PubMed.29460901.s16.e0" text="valproate" /><entity charOffset="28-36" id="DDI-PubMed.29460901.s16.e1" text="LTG" /><entity charOffset="63-71" id="DDI-PubMed.29460901.s16.e2" text="LTG" /><pair ddi="false" e1="DDI-PubMed.29460901.s16.e1" e2="DDI-PubMed.29460901.s16.e1" /><pair ddi="false" e1="DDI-PubMed.29460901.s16.e1" e2="DDI-PubMed.29460901.s16.e0" /><pair ddi="false" e1="DDI-PubMed.29460901.s16.e1" e2="DDI-PubMed.29460901.s16.e2" /><pair ddi="false" e1="DDI-PubMed.29460901.s16.e0" e2="DDI-PubMed.29460901.s16.e0" /><pair ddi="false" e1="DDI-PubMed.29460901.s16.e0" e2="DDI-PubMed.29460901.s16.e2" /></sentence><sentence text="8 [5" /><sentence text="4; 11" /><sentence text="8] mg / l and Cssmax 11" /><sentence text="4 [7" /><sentence text="3; 15" /><sentence text="3] mg/l" /><sentence text=" In the group that received LTG in combination with drug-inducers of glucuronidation, Cssmin was 2"><entity charOffset="28-30" id="DDI-PubMed.29460901.s23.e0" text="LTG" /></sentence><sentence text="5 [1" /><sentence text="99; 4" /><sentence text="32] mg/l, Cssmax 4" /><sentence text="73 [2" /><sentence text="91; 6" /><sentence text="70] mg/l" /><sentence text=" Statistically significant differences in CDR parameter between groups with LTG monotherapy and duotherapy, both with inducer and with inhibitors, as well as between groups of duotherapy with inductors and with inhibitors were obtained"><entity charOffset="76-78" id="DDI-PubMed.29460901.s30.e0" text="LTG" /></sentence><sentence text=" The results of the study indicate a pronounced pharmacokinetic variability of the LTG"><entity charOffset="83-85" id="DDI-PubMed.29460901.s31.e0" text="LTG" /></sentence><sentence text=" Conducting TDM allows the establishment of individual therapeutic concentrations of LTG in blood plasma and setting a correction vector for antiepileptic therapy"><entity charOffset="85-87" id="DDI-PubMed.29460901.s32.e0" text="LTG" /></sentence><sentence text="" /><sentence text="Цель исследования" /><sentence text=" Изучить фармакокинетическую вариабельность ламотриджина и ее клиническое значение" /><sentence text=" Материал и методы" /><sentence text=" Обследовали 100 больных в возрасте от 18 до 77 лет (средний 38,23±14,37 года), страдающих фокальной эпилепсией" /><sentence text=" Монотерапию ламотриджином (ЛТД) получали 54 больных, дуотерапию - 46 (ЛТД и препараты вальпроевой кислоты - 27, ЛТД и препараты-индукторы ферментов печени - 19)" /><sentence text=" Больным проводили терапевтический лекарственный мониторинг (ТЛМ) ЛТД" /><sentence text=" Определялись минимальная (Cssmin)и максимальная (Cssmax) стационарная концентрация ЛТД в плазме крови, отношение концентрации в плазме крови к дозе на 1 кг массы тела (concentration dose ratio - CDR)" /><sentence text=" Результаты и обсуждение" /><sentence text=" В группе монотерапии Cssmin ЛТД составила 5,6±4,65 мг/л, Cssmax - 7,59±5,54 мг/л, в группе дуотерапии ЛТД и вальпроата: Сssmin ЛТД - 7,8 [5,4; 11,8] мг/л, Cssmax - 11,4 [7,3; 15,3] мг/л, ЛТД и препаратов-индукторов глюкуронизации: Сssmin - 2,5 [1,99; 4,32 мг/л), Сssmax - 4,73 [2,91; 6,7] мг/л" /><sentence text=" Получены статистически значимые различия CDR ЛТД между группами моно- и дуотерапии как с индуктором, так и ингибиторами, а также между группами дуотерапии индукторами и ингибиторами" /><sentence text=" Результаты исследования свидетельствуют о выраженной фармакокинетической вариабельности ЛТД" /><sentence text=" ТЛМ позволяет установить индивидуальные терапевтические концентрации ЛТД в плазме крови и задать вектор коррекции противоэпилептической терапии" /><sentence text="" /></document>